← Back to All US Stocks

Dror Ortho-Design, Inc. (DROR) Stock Fundamental Analysis & AI Rating 2026

DROR OTC Dental Equipment & Supplies DE CIK: 0001282980
Updated This Month • Analysis: Mar 23, 2026 • SEC Data: 2025-12-31
Combined AI Rating
STRONG SELL
96% Confidence
STRONG AGREEMENT
STRONG SELL
95% Conf
STRONG SELL
98% Conf

📊 DROR Key Takeaways

Revenue: $2.6K
Net Margin: -99,100.0%
Free Cash Flow: $-2.1M
Current Ratio: 0.08x
Debt/Equity: N/A
EPS: $0.00
AI Rating: STRONG SELL with 95% confidence
Dror Ortho-Design, Inc. (DROR) receives a STRONG SELL rating with 96% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $2.6K, net profit margin of -99,100.0%, Dror Ortho-Design, Inc. demonstrates mixed fundamentals in the Healthcare sector. Below is our complete DROR stock analysis for 2026.

Is Dror Ortho-Design, Inc. (DROR) a Good Investment?

Claude

Dror Ortho-Design faces severe financial distress with negative stockholders' equity of -2.9M, indicating the company is technically insolvent. Despite revenue growth of 156.8% YoY, the company remains unprofitable with -2.5M net loss and negative operating cash flow of -2.1M, suggesting the revenue growth is not sustainable or translating to operational viability. The company's liquidity crisis (0.08x current ratio) combined with liabilities exceeding assets by 2.8M leaves minimal margin for error.

ChatGPT

Dror Ortho-Design, Inc. shows severe fundamental weakness: revenue is effectively negligible at $2.57K while losses remain in the multi-million-dollar range, producing deeply negative operating and net margins. The balance sheet is distressed, with negative equity, a current ratio of just 0.08x, and persistent negative operating cash flow, indicating the business is not currently self-sustaining and likely dependent on external financing.

Why Buy Dror Ortho-Design, Inc. Stock? DROR Key Strengths

Claude
  • + Year-over-year revenue growth of 156.8% shows demand for products
  • + Cash reserves of 228.5K provide short-term operational runway
  • + Operating loss improved from prior year (net loss up 55.9% YoY, though still negative)
ChatGPT
  • + Revenue grew 156.8% year over year, indicating some top-line activity improvement from a very small base
  • + Cash of $228.54K provides limited near-term liquidity relative to asset size
  • + Net loss improved year over year, suggesting losses narrowed from the prior period

DROR Stock Risks: Dror Ortho-Design, Inc. Investment Risks

Claude
  • ! Negative stockholders' equity of -2.9M indicates technical insolvency and bankruptcy risk
  • ! Operating cash flow of -2.1M exceeds revenue by 808x, demonstrating operational cash burn unsustainable at current scale
  • ! Current ratio of 0.08x represents severe liquidity crisis with liabilities 12.5x current assets
  • ! Negative operating margin of -86,565% and net margin of -99,100% reveal business model dysfunction
  • ! No insider buying activity in last 90 days suggests lack of management confidence
  • ! Total liabilities (3.1M) exceed total assets (258.9K) by 1,100%, creating covenant violation risk
ChatGPT
  • ! Revenue base is immaterial relative to the cost structure, resulting in extreme negative margins and poor growth quality
  • ! Negative stockholders equity and liabilities far exceeding assets indicate balance-sheet distress
  • ! Operating cash burn of $2.06M with a 0.08x current ratio points to substantial liquidity and going-concern risk

Key Metrics to Watch

Claude
  • * Quarterly cash burn rate and path to cash runway depletion
  • * Whether revenue growth sustains or reverses as cash constraints tighten
  • * Changes in stockholders' equity and whether company achieves GAAP profitability
ChatGPT
  • * Quarterly revenue growth versus operating expense trend
  • * Cash runway, operating cash flow, and any improvement in working capital or equity position

Dror Ortho-Design, Inc. (DROR) Financial Metrics & Key Ratios

Revenue
$2.6K
Net Income
$-2.5M
EPS (Diluted)
$0.00
Free Cash Flow
$-2.1M
Total Assets
$258.9K
Cash Position
$228.5K

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

DROR Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin -86,565.0%
Net Margin -99,100.0%
ROE N/A
ROA -982.8%
FCF Margin -80,179.6%

DROR vs Healthcare Sector: How Dror Ortho-Design, Inc. Compares

How Dror Ortho-Design, Inc. compares to Healthcare sector averages

Net Margin
DROR -99,100.0%
vs
Sector Avg 12.0%
DROR Sector
ROE
DROR 0.0%
vs
Sector Avg 15.0%
DROR Sector
Current Ratio
DROR 0.1x
vs
Sector Avg 2.0x
DROR Sector
Debt/Equity
DROR 0.0x
vs
Sector Avg 0.6x
DROR Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Dror Ortho-Design, Inc. Stock Overvalued? DROR Valuation Analysis 2026

Based on fundamental analysis, Dror Ortho-Design, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
N/A
Sector avg: 15%
Net Profit Margin
-99,100.0%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Dror Ortho-Design, Inc. Balance Sheet: DROR Debt, Cash & Liquidity

Current Ratio
0.08x
Quick Ratio
0.08x
Debt/Equity
N/A
Debt/Assets
1,209.8%
Interest Coverage
-158,784.86x
Long-term Debt
N/A

DROR Revenue & Earnings Growth: 5-Year Financial Trend

DROR 5-year financial data: Year 2020: Revenue $1.0K, Net Income N/A, EPS N/A. Year 2021: Revenue $2.6K, Net Income -$168.0K, EPS $0.00. Year 2022: Revenue $2.6K, Net Income -$170.5K, EPS $0.00.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Dror Ortho-Design, Inc.'s revenue has grown significantly by 157% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.01 indicates the company is currently unprofitable.

DROR Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-80,179.6%
Free cash flow / Revenue

DROR Quarterly Earnings & Performance

Quarterly financial performance data for Dror Ortho-Design, Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2022 $913 -$27.2K $0.00
Q2 2022 $460 -$36.9K $0.00
Q1 2022 $1.2K -$47.5K $0.00
Q3 2021 $913 -$27.2K N/A
Q2 2021 $460 -$31.6K N/A
Q1 2021 $1.0K -$47.5K N/A
Q3 2020 $1.0K -$34.4K N/A
Q2 2020 $1.0K -$26.7K N/A

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Dror Ortho-Design, Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$2.1M
Cash generated from operations
Capital Expenditures
$966
Investment in assets
Dividends
None
No dividend program

DROR SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Dror Ortho-Design, Inc. (CIK: 0001282980)

📋 Recent SEC Filings

Date Form Document Action
Apr 1, 2026 S-1/A ea0283974-s1a3_drorortho.htm View →
Mar 4, 2026 8-K ea0279935-8k_dror.htm View →
Feb 27, 2026 10-K ea0278430-10k_drorortho.htm View →
Feb 3, 2026 S-1/A ea0274999-s1a2_drorortho.htm View →
Jan 6, 2026 8-K ea0271910-8k_dror.htm View →

Frequently Asked Questions about DROR

What is the AI rating for DROR?

Dror Ortho-Design, Inc. (DROR) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 96% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are DROR's key strengths?

Claude: Year-over-year revenue growth of 156.8% shows demand for products. Cash reserves of 228.5K provide short-term operational runway. ChatGPT: Revenue grew 156.8% year over year, indicating some top-line activity improvement from a very small base. Cash of $228.54K provides limited near-term liquidity relative to asset size.

What are the risks of investing in DROR?

Claude: Negative stockholders' equity of -2.9M indicates technical insolvency and bankruptcy risk. Operating cash flow of -2.1M exceeds revenue by 808x, demonstrating operational cash burn unsustainable at current scale. ChatGPT: Revenue base is immaterial relative to the cost structure, resulting in extreme negative margins and poor growth quality. Negative stockholders equity and liabilities far exceeding assets indicate balance-sheet distress.

What is DROR's revenue and growth?

Dror Ortho-Design, Inc. reported revenue of $2.6K.

Does DROR pay dividends?

Dror Ortho-Design, Inc. does not currently pay dividends.

Where can I find DROR SEC filings?

Official SEC filings for Dror Ortho-Design, Inc. (CIK: 0001282980) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is DROR's EPS?

Dror Ortho-Design, Inc. has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is DROR a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Dror Ortho-Design, Inc. has a STRONG SELL rating with 96% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is DROR stock overvalued or undervalued?

Valuation metrics for DROR: ROE of N/A (sector avg: 15%), net margin of -99,100.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy DROR stock in 2026?

Our dual AI analysis gives Dror Ortho-Design, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is DROR's free cash flow?

Dror Ortho-Design, Inc.'s operating cash flow is $-2.1M, with capital expenditures of $966.0. FCF margin is -80,179.6%.

How does DROR compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin -99,100.0% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.08 (avg: 2).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 23, 2026 | Data as of: 2025-12-31 | Powered by Claude AI